Liquidia Technologies is trading 4.05% down at $68.08 after Zacks Research downgraded it from hold to strong sell on September 24, 2026, citing intensifying pulmonary arterial hypertension competition that could limit Yutrepia’s growth.
- A market-wide explanation appears less likely: major U.S. indices are modestly higher or flat.
- Yutrepia remains Liquidia’s key growth driver, but investors appear focused on competitive pressure despite recent commercial momentum.